BiotechTube

R-mabHDI and ABVD + ABVD

Phase 3UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hodgkin's Lymphoma

Conditions

Hodgkin's Lymphoma

Trial Timeline

Jul 1, 2011 → Apr 1, 2014

NCT ID
NCT00816959

About R-mabHDI and ABVD + ABVD

R-mabHDI and ABVD + ABVD is a phase 3 stage product being developed by Eli Lilly for Hodgkin's Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00816959. Target conditions include Hodgkin's Lymphoma.

What happened to similar drugs?

8 of 20 similar drugs in Hodgkin's Lymphoma were approved

Approved (8) Terminated (2) Active (10)
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved
✅rituximab [MabThera/Rituxan]RocheApproved
✅TenofovirGilead SciencesApproved
✅temsirolimus + temsirolimusPfizerApproved
✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved
✅Entecavir prophylaxis + Therapeutic entecavirBristol Myers SquibbApproved
✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved

Hype Score Breakdown

Clinical
17
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00816959Phase 3UNKNOWN

Competing Products

20 competing products in Hodgkin's Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
32
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
32
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
R-mabHD + ABVDEli LillyPhase 2
31
LY317615Eli LillyPhase 2
35
LY4584180 + RituximabEli LillyPhase 1
36
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
40
HRS-3738Jiangsu Hengrui MedicinePhase 1
25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
31
ABT-199 + KetoconazoleAbbViePhase 1
29
ABT-199 + RifampinAbbViePhase 1
21
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21
ABT-199 + Rituximab + BendamustineAbbViePhase 1
29